Profusa has entered into a distribution agreement with MedSell to commercialize its Lumee Oxygen tissue monitoring device in France, adding to existing partnerships in Spain, Germany, the Benelux region, Austria, the United Kingdom and Scandinavia. With this new alliance, Profusa’s network now addresses approximately 200,000 critical limb ischemia cases annually across the European Union. The French collaboration is further supported by a key opinion leader partnership with Dr. Yann Gouëffic at Groupe Hospitalier Paris Saint Joseph, whose practice accounts for roughly 8% of all CLTI cases in France. Profusa projects revenues of $0.5–2.0 million in 2026, $9–13 million in 2027 and aims to reach $200–250 million by 2030 through this expanded footprint and ongoing clinical validation in both hospital and outpatient wound-care settings.

Profusa has restructured its Senior Secured Convertible Notes to enhance balance sheet flexibility and reduce potential dilution. The amended terms eliminate mandatory amortization payments that had been scheduled to begin in early 2026, raise the conversion floor price to $0.35 from $0.10, and extend the final maturity to 18 months post-issuance. In addition, mandatory equity-linked credit facility payments will increase from 33% to 50% on shares issued under any new Form S-1 registration. The company expects these changes to lower near-term cash requirements, preserve shareholder value and allow management to focus resources on commercial launch activities, inventory build and new partnership development in 2026.